DE60029602D1 - Lipasehemmer enthaltende dispersionsformulierungen - Google Patents

Lipasehemmer enthaltende dispersionsformulierungen

Info

Publication number
DE60029602D1
DE60029602D1 DE60029602T DE60029602T DE60029602D1 DE 60029602 D1 DE60029602 D1 DE 60029602D1 DE 60029602 T DE60029602 T DE 60029602T DE 60029602 T DE60029602 T DE 60029602T DE 60029602 D1 DE60029602 D1 DE 60029602D1
Authority
DE
Germany
Prior art keywords
hemmer
lipase
containing dispersion
dispersion formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60029602T
Other languages
English (en)
Other versions
DE60029602T2 (de
Inventor
Smidt Christiaan De
Paul Hadvary
Hans Lengsfeld
Thomas Rades
Hans Steffen
Joseph Tardio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60029602(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60029602D1 publication Critical patent/DE60029602D1/de
Publication of DE60029602T2 publication Critical patent/DE60029602T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60029602T 1999-09-13 2000-09-11 Lipasehemmer enthaltende dispersionsformulierungen Expired - Lifetime DE60029602T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99118180 1999-09-13
EP99118180 1999-09-13
PCT/EP2000/008858 WO2001019340A1 (en) 1999-09-13 2000-09-11 Dispersion formulations containing lipase inhibitors

Publications (2)

Publication Number Publication Date
DE60029602D1 true DE60029602D1 (de) 2006-09-07
DE60029602T2 DE60029602T2 (de) 2007-07-26

Family

ID=8238990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60029602T Expired - Lifetime DE60029602T2 (de) 1999-09-13 2000-09-11 Lipasehemmer enthaltende dispersionsformulierungen

Country Status (39)

Country Link
US (3) US20030181512A1 (de)
EP (1) EP1216025B1 (de)
JP (1) JP4217016B2 (de)
KR (1) KR100572434B1 (de)
CN (1) CN1197551C (de)
AR (1) AR025587A1 (de)
AT (1) ATE333866T1 (de)
AU (1) AU769415B2 (de)
BR (2) BR0013939A (de)
CA (1) CA2383916C (de)
CO (1) CO5180587A1 (de)
CY (1) CY1106180T1 (de)
CZ (1) CZ301901B6 (de)
DE (1) DE60029602T2 (de)
DK (1) DK1216025T3 (de)
EG (1) EG24117A (de)
ES (1) ES2267563T3 (de)
HK (1) HK1049966A1 (de)
HR (1) HRP20020205B1 (de)
HU (1) HU228858B1 (de)
IL (1) IL148494A0 (de)
JO (1) JO2386B1 (de)
MA (1) MA26818A1 (de)
ME (1) MEP90808A (de)
MX (1) MXPA02002034A (de)
MY (1) MY130200A (de)
NO (1) NO331906B1 (de)
NZ (1) NZ517545A (de)
PE (1) PE20010595A1 (de)
PL (1) PL199870B1 (de)
PT (1) PT1216025E (de)
RS (1) RS50422B (de)
RU (1) RU2239428C2 (de)
SI (1) SI1216025T1 (de)
TR (1) TR200200606T2 (de)
TW (1) TWI243060B (de)
UY (1) UY26338A1 (de)
WO (1) WO2001019340A1 (de)
ZA (1) ZA200201518B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1307264T1 (en) 2000-07-28 2005-02-28 F. Hoffmann-La Roche Ag New pharmaceutical composition
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
AU2006236564B2 (en) * 2005-04-15 2011-02-17 Tolmar, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
PL1897558T3 (pl) * 2005-06-09 2014-01-31 Norgine Bv Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
EP1970051A1 (de) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Verwendung einer wässrigen Mikroemulsion zur Herstellung einer Formulierung zur Behandlung von Adipositas-Erkrankungen
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
PL2036575T3 (pl) * 2007-09-12 2011-02-28 Mader S R L Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
EP2044930A1 (de) * 2007-10-01 2009-04-08 Nestec S.A. Zusammensetzung zur Steuerung Lipase-katalysierter Reaktionen
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
KR20100075260A (ko) * 2008-12-24 2010-07-02 주식회사종근당 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
WO2016166767A1 (en) * 2015-04-14 2016-10-20 Zim Laboratories Limited Pharmaceutical formulation comprising low melting, highly lipophilic drugs
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法
MY196635A (en) * 2018-06-22 2023-04-25 Sime Darby Plantation Intellectual Property Sdn Bhd Method For Reducing Formation of Free Fatty Acids in Plants
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
CN114983938A (zh) * 2022-05-19 2022-09-02 广东嘉博制药有限公司 一种奥利司他口服复合乳液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
IT1282673B1 (it) 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
EP1017366A4 (de) 1996-09-01 2006-03-22 Pharmos Corp Feste kopräzipitate zur verbesserten bioverfügbarkeit lipophiler substanzen
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
DK1017408T3 (da) * 1997-02-05 2005-08-01 Hoffmann La Roche Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
ES2217797T3 (es) 1998-08-14 2004-11-01 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Also Published As

Publication number Publication date
US8012494B2 (en) 2011-09-06
JP4217016B2 (ja) 2009-01-28
ZA200201518B (en) 2003-07-30
EG24117A (en) 2008-07-06
BRPI0013939B1 (pt) 2017-07-18
HRP20020205A2 (en) 2004-04-30
CA2383916A1 (en) 2001-03-22
TR200200606T2 (tr) 2002-07-22
TWI243060B (en) 2005-11-11
UY26338A1 (es) 2000-10-31
US20110275706A1 (en) 2011-11-10
US20040175420A1 (en) 2004-09-09
AR025587A1 (es) 2002-12-04
JP2003509357A (ja) 2003-03-11
HUP0202737A3 (en) 2005-01-28
PE20010595A1 (es) 2001-05-26
CN1373656A (zh) 2002-10-09
HUP0202737A2 (hu) 2003-01-28
US20030181512A1 (en) 2003-09-25
CO5180587A1 (es) 2002-07-30
HRP20020205B1 (en) 2011-06-30
MXPA02002034A (es) 2002-08-20
PL199870B1 (pl) 2008-11-28
CA2383916C (en) 2009-01-20
CY1106180T1 (el) 2011-06-08
PT1216025E (pt) 2006-12-29
EP1216025B1 (de) 2006-07-26
RU2239428C2 (ru) 2004-11-10
NO331906B1 (no) 2012-04-30
MA26818A1 (fr) 2004-12-20
HK1049966A1 (en) 2003-06-06
CZ20021276A3 (cs) 2003-04-16
AU769415B2 (en) 2004-01-29
YU17202A (sh) 2006-01-16
ME00674B (me) 2011-12-20
PL356174A1 (en) 2004-06-14
BR0013939A (pt) 2002-05-14
ES2267563T3 (es) 2007-03-16
WO2001019340A1 (en) 2001-03-22
MY130200A (en) 2007-06-29
NO20021204D0 (no) 2002-03-12
NO20021204L (no) 2002-03-12
DE60029602T2 (de) 2007-07-26
NZ517545A (en) 2003-11-28
EP1216025A1 (de) 2002-06-26
DK1216025T3 (da) 2006-10-30
CZ301901B6 (cs) 2010-07-28
RS50422B (sr) 2009-12-31
KR100572434B1 (ko) 2006-04-18
CN1197551C (zh) 2005-04-20
ATE333866T1 (de) 2006-08-15
IL148494A0 (en) 2002-09-12
SI1216025T1 (sl) 2006-12-31
JO2386B1 (en) 2007-06-17
HU228858B1 (en) 2013-06-28
MEP90808A (en) 2011-12-20
KR20020063852A (ko) 2002-08-05
AU7286300A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
DE60029602D1 (de) Lipasehemmer enthaltende dispersionsformulierungen
PT973527E (pt) Formulacoes de libertacao prolongada de claritromicina
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
IS2325B (is) Örgerðar samsetningar epleróns
PT1096937E (pt) Formulacoes de ranolazina de libertacao prolongada
MA24473A1 (fr) Formulations
PT1139739E (pt) Formulacoes agroquimicas
ID25533A (id) Formulasi 2-metil-tieno-benzodiazepin
DK0853945T3 (da) Flydende gonadotropinholdige formuleringer
PT1130966E (pt) Formulacoes antiparasitarias
DE59907942D1 (de) Vormischbrenner
PT1109449E (pt) Formulacoes de microcapsulas
NO20012265L (no) Dispergerbare preparater inneholdende L-DOPA-ethylester
ATE259590T1 (de) Pour-on formulierungen
IS6398A (is) Lyfjablöndur
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
ATE232683T1 (de) Mikrokapsel-formulierungen
NO20002590D0 (no) Formuleringer omfattende oppløst paroxetin
DE60010151D1 (de) Vormischbrenner
FR2799889B1 (fr) Connecteur demontable
NO980285D0 (no) Forgrenet muffe
SE9903391D0 (sv) Novel formulation
SE9803106D0 (sv) Novel formulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition